• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Complete response after neoadjuvant therapy : How certain is the pathology?].

作者信息

Tischoff Iris, Tannapfel Andrea

机构信息

Institut für Pathologie, Ruhr-Universität Bochum, Universitätskliniken Bergmannsheil, Bürkle-de-la-Camp Platz 1, 44789, Bochum, Deutschland.

出版信息

Chirurg. 2022 Feb;93(2):115-122. doi: 10.1007/s00104-021-01510-w. Epub 2021 Oct 6.

DOI:10.1007/s00104-021-01510-w
PMID:34613440
Abstract

Histopathologic evaluation of tumors after neoadjuvant therapy is performed by tumor regression grading (TRG) systems, which reflect the proportion of vital residual primary tumor in relation to the previous total tumor. The World Health Organization (WHO) tumor grading is replaced by TRG in tumor classification. The histopathological work-up of a tumor is based on the criteria of the TNM classification even after neoadjuvant therapy. A uniform TRG does not exist. For various tumors TRGs based on the tumor entity have been established, consisting of a 3-stage or 5‑stage grading system. Complete histopathological tumor regression is only present if no vital tumor cells are detectable in the histopathological examination of the primary surgical specimens (primary tumor and accompanying locoregional lymph nodes) and there are no distant metastases.

摘要

相似文献

1
[Complete response after neoadjuvant therapy : How certain is the pathology?].
Chirurg. 2022 Feb;93(2):115-122. doi: 10.1007/s00104-021-01510-w. Epub 2021 Oct 6.
2
Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.膀胱癌新辅助化疗后的肿瘤退缩分级:一种预测生存的新的、成功的策略。
Am J Surg Pathol. 2014 Mar;38(3):325-32. doi: 10.1097/PAS.0000000000000142.
3
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.多中心验证新辅助化疗后肌层浸润性膀胱癌的组织病理学肿瘤消退分级。
Am J Surg Pathol. 2019 Dec;43(12):1600-1610. doi: 10.1097/PAS.0000000000001371.
4
[Regression grading in gastrointestinal tumors].
Pathologe. 2012 Feb;33(1):53-60. doi: 10.1007/s00292-011-1545-9.
5
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.新辅助化疗后胃腺癌五种肿瘤退缩分级系统的比较:一项来自中国国家癌症中心192例病例的回顾性研究
BMC Gastroenterol. 2017 Mar 14;17(1):41. doi: 10.1186/s12876-017-0598-5.
6
[Grading of tumor regression of gastrointestinal carcinomas after neoadjuvant therapy].[新辅助治疗后胃肠道癌的肿瘤消退分级]
Pathologe. 2022 Feb;43(1):51-56. doi: 10.1007/s00292-021-01041-5. Epub 2021 Dec 23.
7
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.局部晚期结直肠癌新辅助化疗:肝转移灶、原发灶和区域淋巴结组织学应答的比较。
Ann Surg Oncol. 2010 Oct;17(10):2714-9. doi: 10.1245/s10434-010-1056-6. Epub 2010 Apr 20.
8
Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey.新辅助治疗食管胃结合部腺癌后肿瘤退缩分级:国际德尔菲共识调查结果。
Hum Pathol. 2021 Feb;108:60-67. doi: 10.1016/j.humpath.2020.11.001. Epub 2020 Nov 19.
9
Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.新辅助治疗后胃肠道癌的肿瘤退缩分级
Virchows Arch. 2018 Feb;472(2):175-186. doi: 10.1007/s00428-017-2232-x. Epub 2017 Sep 16.
10
Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.组织形态学肿瘤消退和淋巴结转移决定食管癌新辅助放化疗后的预后:对反应分类的意义
Ann Surg. 2005 Nov;242(5):684-92. doi: 10.1097/01.sla.0000186170.38348.7b.

引用本文的文献

1
Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China.诱导化疗联合卡瑞利珠单抗同步放化疗治疗非流行地区局部晚期鼻咽癌:一项中国北方的2期临床试验
BMC Med. 2025 Feb 27;23(1):126. doi: 10.1186/s12916-025-03964-9.